Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drug works best for racing heart after simple maneuver fails?

NCT ID NCT07456423

Disease control Sponsor: Haseki Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 140 adults who came to the emergency room with a fast heart rhythm called AVNRT. After a simple breathing and pushing technique (Valsalva maneuver) didn't work, patients received either adenosine or diltiazem through an IV. The goal was to see which drug more effectively and safely restored a normal heart rhythm.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
adenosine and diltiazem
What this could lead to
If successful, this could help doctors choose the best drug to quickly and safely restore normal heart rhythm in emergency room patients with a specific type of fast heartbeat.
What could go wrong
This is a completed Phase 4 trial with 140 participants, so results are available but may not apply to all patients. Both drugs have known side effects like flushing, chest discomfort, or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

140 people

The number who actually took part.

Started

Jul 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Presentation to the emergency department with hemodynamically stable, regular narrow-complex SVT consistent with AVNRT * a regular narrow-complex tachycardia with QRS duration \<120 ms * no discernible P waves on the presenting rhythm strip or 12-lead ECG * a ventricular rate of 160-220 beats/min Exclusion Criteria: * Contraindications to adenosine or diltiazem (known hypersensitivity to adenosine or diltiazem, prior heart transplantation, or concomitant dipyridamole/carbamazepine therapy) * Clinical evidence of impaired cerebral perfusion (e.g., altered mental status) * Pegnancy * Hemodynamic instability or respiratory failure requiring emergency intubation and advanced life support

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrioventricular nodal re entrant tachycardia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Tachycardia, Atrioventricular Nodal Reentry Tachycardia, Supraventricular

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrioventricular nodal re entrant tachycardia Supraventricular tachycardia (SVT)

Contacts and locations

Locations

  • Haseki Training and Research Hospital

    Istanbul, Fatih, 34265, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.